Elacestrant vs. SOC in patients with ER+/HER- early breast cancer

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

For More Information:

https://clinicaltrials.gov/study/NCT06492616?term=STML-ELA-0422&rank=1